LGALS3 and Alzheimer disease: Given its demonstrated efficacy across multiple pathological cell types and its pharmacokinetic drawbacks, RES represents a compelling candidate for incorporation into the Gal-3-targeted, pathology-tailored delivery strategy, which is well-suited for achieving cell-selective and sustained drug delivery in AD.